Combination Treatment of Rituximab and Therapeutic Vaccines Affords Superior Tumor Suppression and Relapse Prevention for Non‐Hodgkin Lymphoma
Abstract
Abstract Lymphoma, a common malignancy of the lymphatic system, presents considerable health challenges and imposes a significant economic burden. Despite advancements in chemotherapy and immunotherapy that have improved survival rates, issues such as high relapse rates and treatment resistance remain pressing concerns. This study presents a novel therapeutic strategy that combines rituximab with a therapeutic vaccine for human B‐cell non‐Hodgkin lymphoma, evaluated in a humanized mouse model. This combination therapy synergistically achieves superior tumor suppression and relapse prevention. By harnessing the tumor‐killing efficacy of monoclonal antibodies and the T cell‐mediated immunity elicited by vaccines, this approach represents a promising advancement in achieving significantly improved cancer treatment outcomes.
Article Details
Authors (13)
Tong Qi
Heilongjiang Provincial Key Laboratory of Quantum Control, Harbin University of Science and Technology , Harbin 150080,
Jimin Guo
College of Materials Sciences and Engineering, Beijing University of Chemical Technology
Zheng Cao
Department of Biochemistry, Stanford University School of Medicine
Shilin Chen
Center for AIE Research, College of Materials Science and Engineering
Eugene Kimura
UCLA AIDS Institute University of California Los Angeles Los Angeles CA 90095 USA
Xiyao Li
Emiko Kranz
UCLA AIDS Institute University of California Los Angeles Los Angeles CA 90095 USA
Xinheng Guo
Department of Chemical and Biomolecular Engineering University of California Los Angeles Los Angeles CA 90095 USA
Wenting Chen
Beijing Institute of Nanoenergy and Nanosystems
Zi Wang
Cun‐yu Wang
Department of Bioengineering University of California Los Angeles Los Angeles CA 90095 USA
Yunfeng Lu
Jing Wen